Conformational modulation of the farnesoid X receptor by prenylflavonoids: Insights from hydrogen deuterium exchange mass spectrometry (HDX-MS), fluorescence titration and molecular docking studies

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1864, Issue 12, 2016, Pages 1667-1677

  Yang, Liping ^a   Broderick, David ^a   Campbell, Yan ^a,b   Gombart, Adrian F ^a,b   Stevens, Jan F ^a,b   Jiang, Yuan ^a   Hsu, Victor L ^a   Bisson, William H ^a   Maier, Claudia S ^a,b  

^a OREGON STATE UNIVERSITY   (United States)

^b OREGON STATE UNIVERSITY   (United States)

Author keywords

Farnesoid X receptor; Fluorescence spectroscopy; Hydrogen deuterium exchange; Mass spectrometry; Prenylflavonoids; Xanthohumol

Indexed keywords

8 PRENYLNARINGENIN; CHALCONE DERIVATIVE; FARNESOID X RECEPTOR; FLAVONOID; ISOXANTHOHUMOL; TETRAHYDROXANTHOHUMOL; UNCLASSIFIED DRUG; XANTHOHUMOL;

ARTICLE; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; DEUTERIUM HYDROGEN EXCHANGE; DISSOCIATION CONSTANT; DRUG BINDING SITE; DRUG RECEPTOR BINDING; FLUORESCENCE; HUMULUS LUPULUS; LIGAND BINDING; MASS SPECTROMETRY; METABOLIC SYNDROME X; MOLECULAR DOCKING; MOLECULAR RECOGNITION; OBESITY; PRIORITY JOURNAL; PROTEIN DOMAIN;

EID: 84987986872     PISSN: 15709639     EISSN: 18781454     Source Type: Journal    
DOI: 10.1016/j.bbapap.2016.08.019     Document Type: Article

References (66)

1. [1] Mencarelli, A., Fiorucci, S., FXR an emerging therapeutic target for the treatment of atherosclerosis. J. Cell. Mol. Med. 14 (2010), 79–92.
2. [2] Goodwin, B., Jones, S.A., Price, R.R., Watson, M.A., McKee, D.D., Moore, L.B., Galardi, C., Wilson, J.G., Lewis, M.C., Roth, M.E., Maloney, P.R., Willson, T.M., Kliewer, S.A., A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell 6 (2000), 517–526.
3. [3] Ma, K., Saha, P.K., Chan, L., Moore, D.D., Farnesoid X receptor is essential for normal glucose homeostasis. J. Clin. Invest. 116 (2006), 1102–1109.
4. [4] Zhang, Y., Kast-Woelbern, H.R., Edwards, P.A., Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation. J. Biol. Chem. 278 (2003), 104–110.
5. [5] Westin, S., Heyman, R.A., Martin, R., FXR, a therapeutic target for bile acid and lipid disorders. Mini-Rev. Med. Chem. 5 (2005), 719–727.
6. [6] Fiorucci, S., Rizzo, G., Donini, A., Distrutti, E., Santucci, L., Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol. Med. 13 (2007), 298–309.
7. [7] Crawley, M.L., Farnesoid X receptor modulators: a patent review. Expert Opin. Ther. Pat. 20 (2010), 1047–1057.
8. [8] Merk, D., Steinhilber, D., Schubert-Zsilavecz, M., Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators. Future Med. Chem. 4 (2012), 1015–1036.
9. [9] Sepe, V., Festa, C., Renga, B., Carino, A., Cipriani, S., Finamore, C., Masullo, D., Del Gaudio, F., Monti, M.C., Fiorucci, S., Zampella, A., Insights on FXR selective modulation. Speculation on bile acid chemical space in the discovery of potent and selective agonists. Sci. Rep., 6, 2016, 19008.
10. [10] Parks, D.J., Blanchard, S.G., Bledsoe, R.K., Chandra, G., Consler, T.G., Kliewer, S.A., Stimmel, J.B., Willson, T.M., Zavacki, A.M., Moore, D.D., Lehmann, J.M., Bile acids: natural ligands for an orphan nuclear receptor. Science 284 (1999), 1365–1368.
11. [11] De Marino, S., Ummarino, R., D'Auria, M.V., Chini, M.G., Bifulco, G., Renga, B., D'Amore, C., Fiorucci, S., Debitus, C., Zampella, A., Theonellasterols and conicasterols from Theonella swinhoei. Novel marine natural ligands for human nuclear receptors. J. Med. Chem. 54 (2011), 3065–3075.
12. [12] Sepe, V., Bifulco, G., Renga, B., D'Amore, C., Fiorucci, S., Zampella, A., Discovery of sulfated sterols from marine invertebrates as a new class of marine natural antagonists of farnesoid-X-receptor. J. Med. Chem. 54 (2011), 1314–1320.
13. [13] Choi, H., Hwang, H., Chin, J., Kim, E., Lee, J., Nam, S.J., Lee, B.C., Rho, B.J., Kang, H., Tuberatolides, potent FXR antagonists from the Korean marine tunicate Botryllus tuberatus. J. Nat. Prod. 74 (2011), 90–94.
14. [14] Di Leva, F.S., Festa, C., D'Amore, C., De Marino, S., Renga, B., D'Auria, M.V., Novellino, E., Limongelli, V., Zampella, A., Fiorucci, S., Binding mechanism of the farnesoid X receptor marine antagonist suvanine reveals a strategy to forestall drug modulation on nuclear receptors. Design, synthesis, and biological evaluation of novel ligands. J. Med. Chem. 56 (2013), 4701–4717.
15. [15] Sepe, V., Ummarino, R., D'Auria, M.V., Taglialatela-Scafati, O., Marino, S.D., D'Amore, C., Renga, B., Chini, M.G., Bifulco, G., Nakao, Y., Fusetani, N., Fiorucci, S., Zampella, A., Preliminary structure-activity relationship on theonellasterol, a new chemotype of FXR antagonist, from the marine sponge Theonella swinhoei. Mar. Drugs. 10 (2012), 2448–2466.
16. [16] Shin, K., Chin, J., Hahn, D., Lee, J., Hwang, H., Won, D.H., Ham, J., Choi, H., Kang, E., Kim, H., Ju, M.K., Nam, S.J., Kang, H., Sterols from a soft coral, Dendronephthya gigantea as farnesoid X-activated receptor antagonists. Steroids 77 (2012), 355–359.
17. [17] Del Bas, J.M., Ricketts, M.L., Vaque, M., Sala, E., Quesada, H., Ardevol, A., Salvado, M.J., Blay, M., Arola, L., Moore, D.D., Pujadas, G., Fernandez-Larrea, J., Blade, C., Dietary procyanidins enhance transcriptional activity of bile acid-activated FXR in vitro and reduce triglyceridemia in vivo in a FXR-dependent manner. Mol. Nutr. Food Res. 53 (2009), 805–814.
18. [18] Heidker, R.M., Caiozzi, G.C., Ricketts, M.L., Dietary procyanidins selectively modulate intestinal farnesoid X receptor-regulated gene expression to alter enterohepatic bile acid recirculation: elucidation of a novel mechanism to reduce triglyceridemia. Mol. Nutr. Food Res. 60 (2016), 727–736.
19. [19] Li, G., Lin, W., Araya, J.J., Chen, T., Timmermann, B.N., Guo, G.L., A tea catechin, epigallocatechin-3-gallate, is a unique modulator of the farnesoid X receptor. Toxicol. Appl. Pharmacol. 258 (2012), 268–274.
20. [20] Nozawa, H., Xanthohumol, the chalcone from beer hops (Humulus lupulus L.), is the ligand for farnesoid X receptor and ameliorates lipid and glucose metabolism in KK-A(y) mice. Biochem. Biophys. Res. Commun. 336 (2005), 754–761.
21. [21] Campbell, Y., Sinnott, B., Zhen, J., Fantacone, M.L., Esfandiari, E., Yang, L., Maier, C.S., Stevens, J.F., Gombart, A.F., Induction of Human Cathelicidin Antimicrobial Peptide Gene Expression by Xanthohumol via the Farnesoid X Receptor, Molecular Nutrition and Food Research (under Revision). 2016.
22. [22] Tabata, N., Ito, M., Tomoda, H., Omura, S., Xanthohumols, diacylglycerol acyltransferase inhibitors, from Humulus lupulus. Phytochemistry 46 (1997), 683–687.
23. [23] Casaschi, A., Maiyoh, G.K., Rubio, B.K., Li, R.W., Adeli, K., Theriault, A.G., The chalcone xanthohumol inhibits triglyceride and apolipoprotein B secretion in HepG2 cells. J. Nutr. 134 (2004), 1340–1346.
24. [24] Nozawa, H., Xanthohumol, the chalcone from beer hops (Humulus lupulus L.), is the ligand for farnesoid X receptor and ameliorates lipid and glucose metabolism in KK-A(y) mice. Biochem. Biophys. Res. Commun. 336 (2005), 754–761.
25. [25] Yang, J.Y., Della-Fera, M.A., Rayalam, S., Baile, C.A., Effect of xanthohumol and isoxanthohumol on 3T3-L1 cell apoptosis and adipogenesis. Apoptosis 12 (2007), 1953–1963.
26. [26] Chalmers, M.J., Busby, S.A., Pascal, B.D., West, G.M., Griffin, P.R., Differential hydrogen/deuterium exchange mass spectrometry analysis of protein-ligand interactions. Expert Rev. Proteomics 8 (2011), 43–59.
27. [27] Wales, T.E., Engen, J.R., Hydrogen exchange mass spectrometry for the analysis of protein dynamics. Mass Spectrom. Rev. 25 (2006), 158–170.
28. [28] Balasubramaniam, D., Komives, E.A., Hydrogen-exchange mass spectrometry for the study of intrinsic disorder in proteins. Biochim. Biophys. Acta 1834 (2013), 1202–1209.
29. [29] Yan, X., Maier, C.S., Hydrogen/deuterium exchange mass spectrometry. Methods Mol. Biol. 492 (2009), 255–271.
30. [30] Silva, D., Cortez, C.M., Cunha-Bastos, J., Louro, S.R., Methyl parathion interaction with human and bovine serum albumin. Toxicol. Lett. 147 (2004), 53–61.
31. [31] Chao, P.W., Chow, C.S., Monitoring aminoglycoside-induced conformational changes in 16S rRNA through acrylamide quenching. Bioorg. Med. Chem. 15 (2007), 3825–3831.
32. [32] Bakkialakshmi, S., Chandrakala, D., A spectroscopic investigations of anticancer drugs binding to bovine serum albumin. Spectrochim. Acta A Mol. Biomol. Spectrosc. 88 (2012), 2–9.
33. [33] Lakowicz, J.R., SpringerLink (Online Service), Principles of Fluorescence Spectroscopy. 2006, Springer Science + Business Media, LLC, Boston, MA.
34. [34] Yang, L., Broderick, D., Jiang, Y., Hsu, V., Maier, C.S., Conformational dynamics of human FXR-LBD ligand interactions studied by hydrogen/deuterium exchange mass spectrometry: insights into the antagonism of the hypolipidemic agent Z-guggulsterone. Biochim. Biophys. Acta 1844 (2014), 1684–1693.
35. [35] Weis, D.D., Engen, J.R., Kass, I.J., Semi-automated data processing of hydrogen exchange mass spectra using HX-express. J. Am. Soc. Mass Spectrom. 17 (2006), 1700–1703.
36. [36] Sperry, J.B., Huang, R.Y., Zhu, M.M., Rempel, D.L., Gross, M.L., Hydrophobic peptides affect binding of calmodulin and Ca as explored by H/D amide exchange and mass spectrometry. Int. J. Mass Spectrom. 302 (2011), 85–92.
37. [37] Parker, C.H., Morgan, C.R., Rand, K.D., Engen, J.R., Jorgenson, J.W., Stafford, D.W., A conformational investigation of propeptide binding to the integral membrane protein gamma-glutamyl carboxylase using nanodisc hydrogen exchange mass spectrometry. Biochemistry 53 (2014), 1511–1520.
38. [38] Huang, R.Y., Wen, J., Blankenship, R.E., Gross, M.L., Hydrogen-deuterium exchange mass spectrometry reveals the interaction of Fenna-Matthews-Olson protein and chlorosome CsmA protein. Biochemistry 51 (2012), 187–193.
39. [39] Shortridge, M.D., Hage, D.S., Harbison, G.S., Powers, R., Estimating protein-ligand binding affinity using high-throughput screening by NMR. J. Comb. Chem. 10 (2008), 948–958.
40. [40] Wei, H., Mo, J., Tao, L., Russell, R.J., Tymiak, A.A., Chen, G., Iacob, R.E., Engen, J.R., Hydrogen/deuterium exchange mass spectrometry for probing higher order structure of protein therapeutics: methodology and applications. Drug Discov. Today 19 (2014), 95–102.
41. [41] Englander, S.W., Kallenbach, N.R., Hydrogen exchange and structural dynamics of proteins and nucleic acids. Q. Rev. Biophys. 16 (1983), 521–655.
42. [42] Mi, L.Z., Devarakonda, S., Harp, J.M., Han, Q., Pellicciari, R., Willson, T.M., Khorasanizadeh, S., Rastinejad, F., Structural basis for bile acid binding and activation of the nuclear receptor FXR. Mol. Cell 11 (2003), 1093–1100.
43. [43] Jiang, C., Xie, C., Lv, Y., Li, J., Krausz, K.W., Shi, J., Brocker, C.N., Desai, D., Amin, S.G., Bisson, W.H., Liu, Y., Gavrilova, O., Patterson, A.D., Gonzalez, F.J., Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat. Commun., 6, 2015, 10166.
44. [44] Perkins, A., Phillips, J.L., Kerkvliet, N.I., Tanguay, R.L., Perdew, G.H., Kolluri, S.K., Bisson, W.H., A structural switch between agonist and antagonist bound conformations for a ligand-optimized model of the human aryl hydrocarbon receptor ligand binding domain. Biology 3 (2014), 645–669.
45. [45] Garcia, R.A., Pantazatos, D., Villarreal, F.J., Hydrogen/deuterium exchange mass spectrometry for investigating protein-ligand interactions. Assay Drug Dev. Technol. 2 (2004), 81–91.
46. [46] Acharya, K.R., The advantages and limitations of protein crystal structure. Trends Pharmacol. Sci. 26 (2005), 10–14.
47. [47] Hamuro, Y., Coales, S.J., Morrow, J.A., Molnar, K.S., Tuske, S.J., Southern, M.R., Griffin, P.R., Hydrogen/deuterium-exchange (H/D-Ex) of PPARgamma LBD in the presence of various modulators. Protein Sci. 15 (2006), 1883–1892.
48. [48] Zhang, J., Chalmers, M.J., Stayrook, K.R., Burris, L.L., Garcia-Ordonez, R.D., Pascal, B.D., Burris, T.P., Dodge, J.A., Griffin, P.R., Hydrogen/deuterium exchange reveals distinct agonist/partial agonist receptor dynamics within vitamin D receptor/retinoid X receptor heterodimer. Structure 18 (2010), 1332–1341.
49. [49] Bruning, J.B., Chalmers, M.J., Prasad, S., Busby, S.A., Kamenecka, T.M., He, Y., Nettles, K.W., Griffin, P.R., Partial agonists activate PPARgamma using a helix 12 independent mechanism. Structure 15 (2007), 1258–1271.
50. [50] Han, K.C., Kim, J.H., Kim, K.H., Kim, E.E., Seo, J.H., Yang, E.G., Identification of farnesoid X receptor modulators by a fluorescence polarization-based interaction assay. Anal. Biochem. 398 (2010), 185–190.
51. [51] Moreno, F., Gonzalez-Jimenez, J., Binding of the Promen fluorescent probe to human serum albumin: a fluorescence spectroscopic study. Chem. Biol. Interact. 121 (1999), 237–252.
52. [52] Gasymov, O.K., Abduragimov, A.R., Glasgow, B.J., A simple model-free method for direct assessment of fluorescent ligand binding by linear spectral summation. J. Fluoresc. 24 (2014), 231–238.
53. [53] Lehrer, S.S., Solute perturbation of protein fluorescence. The quenching of the tryptophyl fluorescence of model compounds and of lysozyme by iodide ion. Biochemistry 10 (1971), 3254–3263.
54. [54] Wang, Z., Tan, X., Chen, D., Yue, Q., Song, Z., Study on the binding behavior of lysozyme with cephalosporin analogues by fluorescence spectroscopy. J. Fluoresc. 19 (2009), 801–808.
55. [55] Kandagal, P.B., Ashoka, S., Seetharamappa, J., Shaikh, S.M., Jadegoud, Y., Ijare, O.B., Study of the interaction of an anticancer drug with human and bovine serum albumin: spectroscopic approach. J. Pharm. Biomed. Anal. 41 (2006), 393–399.
56. [56] Ding, F., Liu, W., Liu, F., Li, Z.Y., Sun, Y., A study of the interaction between malachite green and lysozyme by steady-state fluorescence. J. Fluoresc. 19 (2009), 783–791.
57. [57] Papadopoulou, A., Green, R.J., Frazier, R.A., Interaction of flavonoids with bovine serum albumin: a fluorescence quenching study. J. Agric. Food Chem. 53 (2005), 158–163.
58. [58] Rasoulzadeh, F., Jabary, H.N., Naseri, A., Rashidi, M.R., Fluorescence quenching study of quercetin interaction with bovine milk xanthine oxidase. Spectrochim. Acta A Mol. Biomol. Spectrosc. 72 (2009), 190–193.
59. [59] Cui, F.L., Fan, J., Li, J.P., Hu, Z.D., Interactions between 1-benzoyl-4-p-chlorophenyl thiosemicarbazide and serum albumin: investigation by fluorescence spectroscopy. Bioorg. Med. Chem. 12 (2004), 151–157.
60. [60] Lakowicz, J.R., Weber, G., Quenching of fluorescence by oxygen. A probe for structural fluctuations in macromolecules. Biochemistry 12 (1973), 4161–4170.
61. [61] Burris, T.P., Montrose, C., Houck, K.A., Osborne, H.E., Bocchinfuso, W.P., Yaden, B.C., Cheng, C.C., Zink, R.W., Barr, R.J., Hepler, C.D., Krishnan, V., Bullock, H.A., Burris, L.L., Galvin, R.J., Bramlett, K., Stayrook, K.R., The hypolipidemic natural product guggulsterone is a promiscuous steroid receptor ligand. Mol. Pharmacol. 67 (2005), 948–954.
62. [62] Modica, S., Gadaleta, R.M., Moschetta, A., Deciphering the nuclear bile acid receptor FXR paradigm. Nucl. Recept. Signal., 8, 2010, e005.
63. [63] Kaldas, M.I., Walle, U.K., van der Woude, H., McMillan, J.M., Walle, T., Covalent binding of the flavonoid quercetin to human serum albumin. J. Agric. Food Chem. 53 (2005), 4194–4197.
64. [64] Hsu, C.W., Zhao, J., Huang, R., Hsieh, J.H., Hamm, J., Chang, X., Houck, K., Xia, M., Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci. Rep., 4, 2014, 6437.
65. [65] Bas, J.M.D., Ricketts, M.-L., Vaqué, M., Sala, E., Quesada, H., Ardevol, A., Salvadó, M.J., Blay, M., Arola, L., Moore, D.D., Pujadas, G., Fernandez-Larrea, J., Bladé, C., Dietary procyanidins enhance transcriptional activity of bile acid-activated FXR in vitro and reduce triglyceridemia in vivo in a FXR-dependent manner. Mol. Nutr. Food Res. 53 (2009), 805–814.
66. [66] Li, G., Lin, W., Araya, J.J., Chen, T., Timmermann, B.N., Guo, G.L., A tea catechin, epigallocatechin-3-gallate, is a unique modulator of the farnesoid X receptor. Toxicol. Appl. Pharmacol. 258 (2012), 268–274.